|
Book |
These chapters were published with modifications by Oxford University Press, 2004 |
Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease |
Book Cover | Preface | Acknowledgments | Contents | Contributors |
PART I: FUNDAMENTALS |
Chapter 1 |
Human
Genome Epidemiology: Scope and Strategies Introduction Vision of Genomic Medicine Nevertheless, many authors have expressed skepticism regarding the value of human genome discoveries to health care and disease prevention (6-10). Concerns cited include the low magnitude of risk for common diseases associated with most genetic variants discovered thus far, the absence of interventions that are specific to different genotypes, and the potential for genetic labeling potentially causing personal and social harms. Furthermore, some public health professionals have expressed concern that too much emphasis on genomics can divert energy and resources from disease prevention strategies that have been proven to be effective on a population basis (e.g., diet, exercise, smoking cessation, 10,11). Nevertheless, leading scientists continue to predict the imminent integration of gene discoveries in medical practice. In 2001, Collins and McKusick stated that: “By the year 2010, it is expected that predictive genetic tests will be available for as many as a dozen common conditions, allowing individuals who wish to know this information to learn their individual susceptibilities and to take steps to reduce those risks for which interventions are or will be available. Such interventions could take the form of medical surveillance, lifestyle modifications, diet, or drug therapy. Identification of persons at highest risk for colon cancer, for example, could lead to targeted efforts to provide colonoscopic screening to those individuals, with the likelihood of preventing many premature deaths” (12). Moreover, commercial marketing of a genomic approach to preventive medicine has already been implemented, albeit prematurely, both in Europe (13) and the United States (14). This scenario of the practice of medicine is based on the assumption that the use of genetic information at multiple gene loci, perhaps in combination with a person’s family history of disease, can stratify people according to their risks for various diseases for targeted medical and behavioral interventions. In one such hypothetical scenario (Table 1-2), John, a 23-year-old college graduate with a high cholesterol level and a paternal history of early onset of myocardial infarction, undergoes a battery of genetic tests. Because of his increased risk for coronary heart disease, a prophylactic drug chosen for its efficacy in people with John's genotype is prescribed to reduce his cholesterol level and the risk for coronary artery disease (15). His risk for colon cancer can be addressed by a program of annual colonoscopy starting at the age of 45, which provides an opportunity for early detection and secondary prevention of colon cancer mortality. Finally, his increased risk for lung cancer is addressed through behavior modification for smoking cessation. Although this case is often used to illustrate future use of genetic information for prevention, it raises a number of issues. For example, it is not clear whether or not genetic information is really needed to target certain interventions, such as smoking cessation or treatment of hypercholesterolemia. In the case of smoking, testing for susceptibility may reduce the motivation for smoking cessation in those individuals who test “normal” for the genotype. Even when genetic information provides guidance-as is the case with early initiation of colorectal cancer screening- the need for a DNA-based test versus the more generic information provided by a family history is open to question. Visions of genomic medicine also include gene therapy (12,16), and a whole generation of smart (or designer) drugs and vaccines that can be tailored to individual genetically mediated response (12). As with preventive strategies guided by genotype, potential uses of genomic information requires rigorous evaluation. How do we get from the sequencing of the human genome to using such knowledge to improve clinical care and disease prevention? Collins and McKusick outlined critical elements of the medical research agenda in the 21st century that include improved laboratory technology, clinical research, evaluation of biologic pathways, and improved drug investigation (pharmacogenomics) (12). However, there will be additional crucial missing gaps in our knowledge base that will be filled by the classical public health sciences (17). This research effort is essential in determining to health risks associated with genetic variants and potential for treatments and prevention. Data in both these areas are also crucial in determining the ethical, legal and social implications of genetic information (18). Table 1-3 illustrates the convergence of several public health fields that will attempt to answer specific questions to allow the effective “translation” of gene discoveries into the realization of a vision of genomic medicine. Obviously, the first question: “what are the risks?” is a crucial one that falls under the purview of epidemiology. In the following chapters we explore how epidemiologic methods can begin to bridge the knowledge gaps to answer this question. The hypothetical relative risks and lifetime disease probabilities presented in Table 1-2 can be derived only from well-designed population-based studies that assess disease risks and gene-gene and gene-environment interaction. When accurate risk estimates are obtained, other disciplines of medicine and public health will need to be applied to determine the appropriate use of such information, addressing questions related to public policy, economics, communication, and measurement of health outcomes (as shown in Table 1-3). Epidemiology: What Are The Risks? In spite of these perceived weaknesses, epidemiologic methods have grown steadily over the past 3 decades (24) and have become increasingly integrated with those of genetics in the discipline of genetic epidemiology, which seeks to find the role of genetic factors in disease occurrence in populations and families (25). Also, we have seen the emergence of molecular epidemiology that seeks to study disease occurrence using biological markers of exposures, susceptibility and effects (26). Increasingly scientific tools such as micro array technology and gene expression profiles (reviewed in chapter 2) will be used to identify and measure the effects of various chemical and biologic exposures on health status in addition to the underlying genetic susceptibility to such exposures. Most gene discoveries are based on studies of high-risk families or selected population groups. Once a gene-disease association is documented, well-conducted epidemiologic studies are needed to quantify the impact of gene variants on the risk for disease, death, and disability and to identify and measure the impact of modifiable risk factors that interact with gene variants. Epidemiologic studies are also required in the process of clinical validation of new genetic tests, and to monitor population use of genetic tests and determine the impact of genetic information on the health and well being of different populations. The results of such studies will help medical and public health professionals design clinical trials, ultimately leading to benefit from benefits from medical, behavioral and environmental interventions. To accomplish this goal, there must be collaboration among epidemiologists, clinical geneticists, laboratory scientists, and medical and public health practitioners from government, professional, academic, industry and consumer organizations. The rapid expansion in the number of reported gene-disease associations may lead to pressure to develop commercial tests before validation of research findings. Therefore there is an urgent need for epidemiologic data generated from multidisciplinary collaboration as a basis for developing medical and public health policy. For example, the appropriate use of genetic testing is currently debated in relation to breast cancer and to BRCA1/2 mutations (chapter 27); Alzheimer disease and the apolipoprotein E-E4 allele (chapter 22); and iron overload and HFE gene mutations (chapter 29). Rational and comprehensive health policies on the use of genetic tests will not be possible until robust population-based epidemiologic data are available regarding the frequency of newly discovered gene variants and associated disease risks. What is Human Genome Epidemiology? As shown in figure 1 and Table 1-4, epidemiologic study applications to the human genome include: 1) gene discovery (the traditional domain of genetic epidemiology, 25); 2) population risk characterization (the domain of molecular epidemiology, 26); and 3) evaluation of genetic information for diagnosis and prevention (including genetic tests and family history information), and for genome-based therapies (applied epidemiology and health services research, 30). The evaluation of genetic information can be done in predicting clinical outcomes (clinical epidemiology) or for population screening and public health assessment (public health epidemiology). The continuum of HuGE represents an extension of the concept of “genetic epidemiology with a capital E” proposed by Duncan Thomas (31) because it emphasizes that epidemiologic applications to the human genome go well beyond the quantitative and statistical methods of gene discovery and characterization. Throughout this book, we focus on how epidemiology, as a multidisciplinary field has begun to address issues related to the post gene discovery with increasing emphasis on characterization of gene effects and genetic tests in populations (what do you do with a gene after you find one?). Table 1-5 shows examples of the types of studies encompassed in the spectrum of human genome epidemiology, including methods for gene discovery (such as linkage analysis), assessing the population prevalence of gene variants, evaluating genotype-disease associations, assessing the impact of gene?environment and gene-gene interaction on disease risk; evaluating the usefulness and impact of genetic information (i.e. tests) for individuals, families and populations. In the past few years, there has been a tremendous increase in the number and scope of human genome epidemiology in the peer-reviewed literature. However, most studies are still in the realm of gene discovery and/or genotype-disease associations. An analysis of abstracts of published HuGE papers for 2001 shows that of the 2402 published articles, 82% reported only on population prevalence of gene variants and gene-disease associations, 15% reported on gene-gene and gene-environment interactions, perhaps reflecting the difficulties in studying interactions, and 3% dealt with evaluation of genetic tests and population screening, reflecting a focus on different types of genes considered for clinical practice or population screening (32). Undoubtedly, in the next few years, the number of papers dealing with evaluation of genetic information in medicine and public health is likely to increase as many gene discoveries progress on the translation pathway. Epidemiologic studies of gene-environment interaction and genetic tests are bound to increase as more genes are discovered, characterized, and used to develop diagnostic and predictive tests. Finally, we can view the role of epidemiology vis-à-vis the suggested paradigm shifts in biology and medicine that are occurring in conjunction with the human genome revolution (Table 1-6). Peltonen and McKusick (33) outlined the progressive shifts occurring in several areas. As shown in Table 1-6, post genome discovery, there will be an increasing shift from studying genetic diseases to studying all diseases, assessing gene products (proteomics), from mapping and sequencing to discovery of genetic variants, from studying single genes to multiple genes, from studying gene actions to studying gene regulations, and finally from diagnostic testing to testing for susceptibility. Epidemiologic methods should play a role in all these areas. Need for Methodologic Standards in Epidemiologic
Studies of the Human Genome In the past few years, several authors have conducted HuGE reviews (36). Using specified guidelines (37), authors have conducted systematic, peer?reviewed synopses of epidemiologic aspects of human genes, prevalence of allelic variants in different populations, population?based disease risk information, gene?environment interaction, and quantitative data on genetic tests and service. These reviews have uncovered the need for unified guidelines that can be used to synthesize results of the increasing number of such studies. In 2002, Cooper et al. (38) proposed guidelines to promote the publication of scientifically meaningful disease association studies through the introduction of methodological standards (with a focus on discovery of candidate genes). Although several groups have addressed guidelines for the evaluation and synthesis of a number of areas (e.g. controlled clinical trials), no such recommendations exist that cover the full spectrum of HuGE studies. In an analysis of the epidemiologic quality of molecular genetic research, Bogardus et al. (39) used seven methodologic standards to evaluate the quality of studies in four mainstream medical journals. They found that in spite of the major molecular genetic advances, 63% of the articles did not comply with two or more quality standards (39). This finding emphasizes the need for methodologic standards in reporting such studies. Based on an expert panel workshop held in 1997, Stroup et al. published a proposal for reporting results of meta-analysis of observational studies in epidemiology (40) but did not specifically address genetic studies. Bruns et al. provided a checklist for reporting of studies of diagnostic accuracy of medical tests (41). A workshop sponsored by the National Cancer Institute led to a monograph on innovative study designs and analytic approaches to the genetic epidemiology of cancer (42). This series of articles were useful in outlining the spectrum of study designs in gene discovery and characterization in relation to disease, but they do not provide concrete guidance on the evaluation and synthesis of such studies. In 2001, an expert panel sponsored by the Centers for Disease Control and Prevention and the National Institutes of Health developed guidelines and recommendations for the evaluation and integration of data from human genome epidemiology with emphasis on studies of (1) prevalence of gene variants and gene-disease associations, (2) gene-environment and gene-gene interactions, and (3) evaluation of genetic tests. Conclusions and recommendations from this workshop have been published (43,44). Thus, progress is being slowly made in defining quality standards for genetic-epidemiological research, but ongoing evaluation is needed to make sure that such guidelines are implemented. Finally, there is increasing interest in the evaluation of genetic tests. The National Institutes of Health-Department of Energy Task Force on Genetic Testing (45) and the Secretary’s Advisory Committee on Genetic Testing (46) have proposed detailed evaluation of new genetic tests. Many of the genetic tests that will emerge in the next decades will be used not only for diagnostic purposes but also to predict the risk of developing disease in otherwise healthy people and to make decisions about potentially preventive interventions or therapies. The utility of genetic tests in this context will depend heavily on the quality of epidemiologic information that summarizes the relation between genotypes and disease and how such relation is modulated by the presence of other factors, such as drugs and environmental exposures, and how risk can be reduced by interventions. These concerns clearly apply to the hypothetical case scenario shown in Table 1-2. Such information will have to be based on properly designed epidemiologic information on genotype-disease associations and gene-gene and gene-environment interaction. In addition, this genetic test report will have to include specific information based on appropriate clinical and epidemiologic outcome studies on how the risk for these diseases can be reduced using medical, behavioral and environmental interventions. The HuGE Map Ahead Section I (fundamentals) describes genomic technologies and their applications (chapter 2), evolving methods of gene discovery (chapter 3), and summarizes the current status of the ethical, legal and social issues for conducting epidemiologic studies of the human genome (with emphasis on informed consent issues). Section II addresses epidemiologic approaches to the study of genotypes in populations (chapter 5) and their relation to diseases, including the assessment of gene-gene and gene-environment interaction (chapters 6-8). In addition, chapters 9 and 10 address synthesis of these studies, including some methodologic standards. Section III deals with the application of epidemiologic methods to assessing genetic information for clinical and public health applications. Chapter 11 lays an epidemiologic foundation for using population level information to make individualized risk prediction for clinical use. Chapter 12 explores population-based concepts around the usefulness of genetic tests in population Chapter 13 discusses the evaluation of genetic tests from a combined clinical-laboratory approach. As gene-drug interactions become more prominent in medical practice, chapter 14 explores an epidemiologic framework for the interface between genetics, pharmacology and medicine. Chapter 15 explores the integration of genetics into controlled clinical trials, and chapters 16 and 17 focus on the role of genetics in clinical practice guideline development both in the United States and the United Kingdom. Finally, section IV uses case studies to illustrate concepts discussed in the first 3 sections in relation to specific disease examples, including gene-environment interactions (pesticides in chapter 18 and oral contraceptive use in chapter 19), chronic diseases (colon cancer in chapter 20, Alzheimer disease in chapter 21, cardiovascular disease in chapter 25, breast cancer in chapter 26 and iron overload in chapter 28), occupational exposures (Berylliosis in chapter 22), newborn screening issues (Fragile X syndrome in chapter 23 and hearing loss in chapter 24), and infectious disease (HIV in chapter 27). These examples are by no means exhaustive, but they do illustrate two points: 1) the spectrum from single gene disorders to complex disorders that involve gene-environment interactions and the application of genomic knowledge to disease prevention, and 2) the need for epidemiologic research to obtain population level information that is crucial for developing health policy and new approaches to practice. Indeed for many of the case studies, the lack of such data represents a primary barrier to developing appropriate health polices related to these of genetic risk information. The readers will discover that our knowledge is rapidly evolving for each one of these examples. Most likely, this information will be outdated soon. Nevertheless, we hope that the basic methodologic foundations for how to approach the process of translation from gene discovery to using genetic information will still apply. Throughout the book, we assume that readers have introductory knowledge of the fields of epidemiology and genetics and we therefore mainly address the interface between the two disciplines. For general readings on epidemiology and epidemiologic methods many excellent books are available (e.g., 24, 47-50). Also, we do not present technical details of genome technologies or statistical methods of gene discoveries using family-based methods but merely an overview of these rapidly changing methods. Our central emphasis is on applying epidemiology to assess the role of genetic variations in health outcomes and to evaluate how such information can be used to improve health and prevent disease. Finally, there is an increasing emphasis on using family history (with or without the use of genetic testing) as a tool for disease prevention and public health (51). Family history is a consistent risk factor for most common diseases and reflects shared genetic and environmental factors. Family history is often used an initial tool to genetic testing and targeted interventions. While this book does not cover family history directly, we recognize that epidemiologic methods and approaches can be applied to the evaluation of family history with or without genetic testing. For further discussions about family history in the context of public health and disease prevention, the readers are referred to a series of workshop papers published in 2003 (52). Ultimately, in order to fulfill the promise of the Human Genome Project in improving health, multidisciplinary medical and public health approaches are needed. At the core of these approaches is the simple question: “what are the risks?” followed by the question “what to do with numbers once you get them?” To get there, we have a HuGE map to follow.
|
Address correspondence to Dr. Khoury at |